> DNDN – If no FDA approval next week--the stock gets clocked back to $2. But if it is approved--$10-$14 is probable.<
Let’s clear up one point that is more than just semantics: Provenge is not getting approved or rejected by the FDA next week—the advisory panel is not an arm of the FDA and its function is merely advisory.
The FDA usually, but not always, follows the advice of the advisory panels. The Agency will complete its review of BLA regardless of what happens next week.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.